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1. Introduction 
1.1 Anatomy and embryology of parathyroid glands 
 
The normal parathyroid gland is oval or spherical in shape, has a distinct yellowish color, and 
averages 2x3x7 mm. The total mean weight of four normal parathyroids is about 150 mg. 
Majority of the population have four parathyroid glands typically located at the posterior 
capsule of the thyroid gland (Fig. 1; Fig.2), however in nearly 15% of individuals more than 
four glands are present. Phylogenetically, the parathyroid glands appear in amphibia, and 
arise from pharyngeal pouches III and IV. They may be arrested in the development as high as  
 
 
 
Fig. 1. Thyroid & parathyroid anatomy 
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Fig. 2. Parathyroid glands anatomy. Left side view 
at the level of the hyoid bone on the way of their descent to their typical location. Occasionally, 
parathyroids may be incorporated into the thyroid gland or thymus (intrathyroidal or 
mediastinal location). Lower (inferior) parathyroid glands (parathyroid III) may be found in 
the anterior mediastinum, while the upper (superior) parathyroids (parathyroid IV) usually 
remain in close association with the upper portion of the lateral thyroid lobes but may descend 
caudally along the esophagus into the posterior mediastinum (Fig. 3).  
 
 
Fig. 3. Computed tomography scan showing a large mediastinal parathyroid adenoma 
(indicated with an arrow) 
The parathyroid glands may lie in front of or behind the internal jugular vein and common 
carotid artery. Parathyroids are usually supplied by a branch of the inferior thyroid artery 
but may be supplied by the superior thyroid or, rarely, the thyroid ima arteries. The vessels 
can be seen entering a hilum-like structure, a feature that may be practically utilized to 
differentiate parathyroid glands from fat. 
2. Physiology 
Parathyroid glands secrete parathyroid hormone (PTH), which together with vitamin D, and 
calcitonin plays a vital role in precise regulation of calcium and phosphorus metabolism in 
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bone, kidney, and gut. PTH and calcitonin work in concert to regulate plasma levels of 
ionized calcium. Fall in the ionized calcium level stimulates the parathyroids to secrete more 
PTH, and inhibits the parafollicular cells within the thyroid to produce less calcitonin. The 
rise in PTH and fall in calcitonin stimulate increased resorption of calcium in the renal 
tubules and from bones, thus more calcium enters the blood, and ionized calcium levels 
normalize. PTH in the blood stream is heterogeneous and consists of the intact hormone, the 
amino terminal (N-terminal) fragment and the carboxyl terminal (C-terminal) fragment.  C-
terminal fragment is biologically inert, whereas N-terminal fragment maintains hormonal 
activity, however substantially lower than the intact hormone. Currently available 
diagnostic tests are capable of intact hormone level determination, which is important for 
reliability of the measurement in particular for intraoperative use.  
3. Primary hyperparathyroidism 
Primary hyperparathyroidism is a disease characterized by autonomous overproduction of 
PTH resulting in hypercalcemia. In majority of cases it is caused by a single parathyroid 
adenoma (80-85%), and less frequently by hyperplasia (10%), multiple adenomas (6%), or 
carcinoma (1%). Currently, primary hyperparathyroidism occurs in 0.1-0.3% of the general 
population and in unselected patients is considered the most common cause of 
hypercalcemia. It is almost three times more common in women than in men, with peak 
incidence between the third and fifth decades.  
Excess production of PTH results in mobilization of calcium from bone and inhibition of the 
renal reabsorption of phosphate, leading to hypercalcemia and hypophosphatemia. Besides, 
it causes a wasting of calcium and phosphorus, which eventually may result in osseous 
mineral loss and osteoporosis. Other conditions which may be associated with 
hyperparathyroidism include nephrocalcinosis, nephrolithiasis, osteitis fibrosa cystica, 
pancreatitis, peptic ulcer, hypertension, and gout. Diagnosis of any of these diseases should 
evoke suspicion for hyperparathyroidism and the patient should be referred for more 
precise tests. 
Hyperparathyroidism is occasionally associated with multiple endocrine neoplasia (MEN) 
type 1, or type 2. MEN type 1 is characterized by tumors of the parathyroid, pituitary, and 
pancreas (hyperparathyroidism, pituitary tumors, and islet cell pancreatic tumors) that may 
lead to gastrinoma (Zollinger-Ellison syndrome), glucagonoma, insulinoma (hypoglycemia), 
somatostatinoma, lipoma and pancreatic polypeptide tumors (PPomas). Adrenocortical 
tumors, carcinoid tumors, and multiple lipomas have also been reported in these patients. 
MEN type 2 is divided into 2 subtypes: MEN 2a and MEN 2b. MEN 2a is characterized by 
hyperparathyroidism associated with pheochromocytoma and thyroid medullary 
carcinoma. Hyperparathyroidism is rare in MEN 2b patients who often have multiple 
neuromas and a marfanoid habitus. 
Parathyroid adenomas may range in weight from 65 mg to over 35 g, but occasionally the 
weight of these tumors may exceed 35g.  Usually the size of the tumor parallels the degree 
of hypercalcemia (the larger the tumor, the more severe hypercalcemia). Microscopic 
examination of parathyroid adenomas shows chief cell, water cell, or, rarely, oxyphil cell 
type.  
Primary parathyroid hyperplasia may be another cause of hyperparathyroidism. This 
condition involves all of the parathyroid glands, which vary considerably in size but are 
usually larger than normal. Microscopic examination may reveal two types: chief cell 
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hyperplasia and water-clear cell hyperplasia. Parathyroid carcinoma is rare but usually 
leads to severe hypercalcemia, and should be suspected at operation when the parathyroid 
gland is hard, has a whitish or irregular capsule, or shows signs of invasiveness. Rupture of 
the parathyroid tumor or breaching of the tumor capsule during rough dissection may 
result in seeding hyperactive tissue. This, and less frequently multiple embryologic rests 
may lead to a rare condition called parathyromatosis characterized by persistent 
hypercalcemia. 
4. Signs and symptoms 
Clinical signs and symptoms of hyperparathyroidism range from barely recognizable by 
patients, like muscle fatigablility, weakness, psychiatric disturbances, constipations, 
polydipsja and polyuria to severely impairing normal activities, like bone and muscle pains, 
nephrolithiasis, nephrocalcinosis, hypertension, peptic ulcer, pancreatitis or gout. Osteitis 
fibrosa cystica with bone pains and deformities, which was a prevailing symptom in 
patients with hyperparathyroidism a few decades ago, now became less frequent because 
majority of cases are detected early in the course of the disease. Also the incidence of renal 
complications decreased markedly and many patients are diagnosed by routine screening 
while still asymptomatic. 
5. Laboratory tests 
Serum calcium, parathyroid hormone and phosphates level are the principal laboratory tests 
used for the diagnosis of hyperparathyroidism. Elevated serum calcium and low phosphates 
are highly suggestive of hyperparathyroidism, however in about 50% of patients serum 
phosphates level is normal. Measurement of serum intact parathyroid hormone (PTH) 
concentration is the key test in diagnostic workout for patients with hypercalcemia, because 
the PTH level is low or nil in all cases except for those caused by primary 
hyperparathyroidism and familial hypocalciuric hypercalcemia, where PTH is markedly 
elevated.  
Complementary laboratory tests include chlorides, protein electrophoretic pattern, alkaline 
phosphatase, creatinine, uric acid and urea nitrogen, urinary calcium, blood hematocrite 
and pH, serum magnesium and ESR. Sometimes, when previous tests are equivocal, 
measurement of nephrogenous cAMP, 1,25-hydroxy vitamin D levels and tubular resorption 
of phosphates may be helpful. Serum chloride concentration is elevated in nearly half of 
patients with hyperparathyroidism and may be a useful diagnostic clue. It’s due to direct 
influence of PTH on the proximal renal tubule decreasing the resorption of bicarbonate, 
which leads to increased resorption of chloride. Other causes of hypercalcemia do not give 
rise in chloride concentration. 
6. Secondary hyperparathyroidism 
Secondary hyperparathyroidism (sHPT) is a condition characterized by excess secretion of 
parathyroid hormone stimulated by external factors, mainly hypocalcemia. Chronic renal 
failure is the most common cause of secondary hyperparathyroidism, as it results in 
hypocalcemia due to impaired conversion of vitamin D into active form, and excessive loss 
of calcium with urine. Sporadically sHPT may be caused by malabsorption, like chronic 
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pancreatitis, small bowel disease or malabsorbtion-dependent bariatric surgery. Prolonged 
stimulation of parathyroid tissue by hypocalcemia results in enlargement of parathyroids in 
the form of their hyperplasia and less frequently parathyroid adenoma.  
7. Tertiary hyperparathyroidism 
Tertiary hyperparathyroidism (tHPT) is a condition of autonomic excessive secretion of 
parathyroid hormone developing from secondary parathyroidism, that maintains despite 
restoration of renal function. It is caused by development of autonomous (unregulated) 
parathyroid function following a prolonged period of persistent parathyroid stimulation. It 
is no longer responsive to treatment by medication and requires surgical removal of three 
and a half parathyroid glands. 
8. Indications for surgical treatment 
Parathyroidectomy is currently recognized as the treatment of choice for patients with 
primary hyperparathyroidism. For virtually all these patients surgical resection of 
hyperactive parathyroid tissue is curative. It provides both metabolic improvement and 
symptoms relief. Medical observation is contraindicated. Furthermore, parathyroidectomy 
is recommended as early as possible in the course of the disease because once systemic 
complications such as renal dysfunction or hypertension develop, they tend to progress 
despite elimination of the underlying hyperparathyroidism. 
9. Preoperative imaging techniques 
Various techniques are currently available for parathyroid glands imaging. Noninvasive 
studies include ultrasonography, scintigraphy, computed tomography (CT) scanning, and 
magnetic resonance imaging (MRI). Scintigraphy with use of the radiopharmaceuticals 
technetium 99mTc  sestamibi or technetium 99mTc  tetrofosmin is widely recommended as the 
preferred imaging technique for parathyroids. Parathyroid selective arteriography or 
selective parathyroid venous sampling have been used occasionally as invasive techniques 
in select cases.  
9.1 Ultrasonography  
Parathyroid ultrasonography is currently the most easily accessible and a relatively 
inexpensive non-invasive test that is routinely used for the assessment of the thyroid and 
parathyroid glands. It is utilized for preoperative investigation in patients with 
hyperparathyroidism not only to localize and visualize enlarged parathyroids, but also to 
rule out thyroid nodules that may need to be evaluated prior to parathyroid surgery. For 
best results a high-frequency (7.5- or 10-MHz) linear ultrasound transducer should be 
available. The patient should be supine with the neck moderately hyperextended. It is 
recommended to start the evaluation from the carotid bifurcation superiorly and proceed 
down to the sternal notch inferiorly and to the carotid artery laterally. 
Normal parathyroids are barely visualized with ultrasonography. Parathyroid adenomas 
appear on gray-scale images as hypoechoic or anechoic, discrete, oval masses. They are 
located posterior to the lobe of the thyroid gland and anterior to the longus colli muscles. 
Usually, the common carotid artery confines the parathyroid-bearing region laterally. An 
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echogenic line separating the thyroid tissue from the enlarged parathyroid gland can be 
often visualized. Cystic changes, lobulations, increased echogenicity due to fatty deposition, 
and occasional calcifications are more frequent in larger adenomas.  
Parathyroid adenomas, in particular lesions larger than 1 cm in diameter, tend to be 
hypervascular, and therefore color Doppler ultrasonography is useful in localizing these 
enlarged glands. Besides, Doppler ultrasound can easily disclose the extrathyroidal vessel 
supplying parathyroid and this finding may constitute a road map to the otherwise 
inconspicuous gland. 
Ultrasonography is efficient in diagnosing cervical parathyroid lesions with reported 
sensitivity up to 80% and specificity up to 90%, but fails to detect majority of parathyroid 
adenomas located in the mediastinum. Additionally, intrathyroidal lesions cannot be 
differentiated as a parathyroid adenoma or thyroid nodule based on imaging only, and a 
biopsy is required. 
9.2 
99m
Tc sestamibi imaging 
Nuclear imaging with use of 99mTechnetium (99mTc) sestamibi  is currently approved as a 
standard technique for preoperative imaging of parathyroid glands.  99mTc sestamibi  is a 
complex of the radioisotope technetium-99mTc with the ligand methoxyisobutylisonitrile 
(MIBI). 99mTc sestamibi, first applied as a myocardial perfusion agent, for parathyroids 
assessment is combined with either sodium iodide I123 or  99mTc pertechnetate in a procedure 
called subtraction scintigraphy. It is based on a fenomenon that 99mTc sestamibi is 
accumulated by both thyroid and abnormal parathyroids, whereas sodium iodide I123 and 
99mTc pertechnetate are taken up by only thyroid tissue. To visualize parathyroids and 
differentiate them from thyroid tissue the sodium iodide I123 or 99mTc -pertechnetate image is 
subtracted from the 99mTc-sestamibi image.  
Another, more recent imaging modality is the dual-phase technique with 99mTc sestamibi as 
the sole imaging agent. Both thyroid tissue and abnormal parathyroid tissue incorporate 
99mTc sestamibi from circulating blood rapidly after intravenous administration. The test is 
based on the differential washout of 99mTc sestamibi from thyroid compared with abnormal 
parathyroids. The rate of washout from hyperactive parathyroid tissue, such as parathyroid 
adenoma, is much slower than that of normal thyroid tissue. Routine protocol includes 
intravenous administration of 20mCi of 99mTc Sestamibi and sequencial acquisition of early 
and delayed images of the neck and upper mediastinum. The early image, obtained 10-15 
minutes after the injection, is called the thyroid phase as 99mTc sestamibi is rapidly taken up 
in the thyroid gland at this time. 1.5-3 hours after the injection the delayed image called the 
parathyroid phase is recorded. At this phase, 99mTc sestamibi has been washed out from 
thyroid but remains accumulated in the hyperactive parathyroid tissue, and this allows for 
localization of abnormal parathyroid glands. Planar images may be complemented with 
lateral or oblique acquisitions, or even SPECT images when appropriate equipment is 
applied. Sensitivity of the 99mTc sestamibi dual phase protocol has been reported to achieve 
70-100%. Small or pedunculated, mobile adenomas may, however, be missed at this test.  
99mTc sestamibi may also be used in minimally invasive parathyroid surgery, as an 
intraoperative adjunct facilitating localization of hyperactive parathyroid adenoma and 
confirming curative resection. The radionuclide is injected 1.5 to 3 hours prior to surgery, 
and a hand-held gamma probe is used to guide the incision, localize the abnormal gland 
and confirm identity of the resected parathyroid tissue ex-vivo. This technique called 
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intraoperative nuclear mapping proved to be successful, and is a standard procedure in a 
number of centers. 
99mTc tetrofosmin is another radiopharmaceutical agent recently introduced into parathyroid 
imaging. It has a slightly different mechanism of accumulation in tissues, but imaging 
characteristics similar to those of 99mTc sestamibi. Also imaging protocols are similar with 
intravenous injections of 20-25 mCi of radionuclide prior to early (10-30 minutes) and 
delayed (1.5-3 hours) acquisition images. 
9.3 Computed tomography (CT) scanning 
Assessment of parathyroid glands with use of a typical CT protocol involves the acquisition 
of contiguous axial 2- to 3-mm images ranging from the hyoid bone down to the carina. 
Nonenhanced images of parathyroid adenomas have an attenuation similar to that of 
muscle. Substantial degree of enhancement is usually shown in parathyroid adenomas after 
administration of contrast material, as these lesions tend to be hypervascular structures. 
Typically, parathyroid adenomas present at CT as enlarged, enhancing, soft-tissue masses in 
the expected location of the parathyroids. The sensitivity of CT in detecting parathyroid 
adenomas attains 90%. However, the use of ionizing radiation and required intravenous 
administration of contrast material accompanied by associated risks are considered 
remarkable disadvantages of this imaging technique. Besides, thyroid nodule, tortuous 
vessel, or laterally displaced esophagus may be misidentified as a false-positive finding, 
whereas small or ectopic lesion, poor visualization of neck structures or distorted neck 
anatomy due to prior surgery may lead to false-negative result. 
9.4 Magnetic resonance imaging 
MRI is occasionally used for parathyroid imaging. A typical MRI protocol for the 
assessment of parathyroids involves axial images of the neck and mediastinum. Images are 
acquired using T1-weighted spin-echo sequences (short recovery time [TR], short echo time 
[TE]) followed by T2-weighted spin-echo sequences (long TR, long TE). Parathyroid 
adenomas are seen on MRI images as soft-tissue masses, whereas normal parathyroids are 
usually not detected. Parathyroid adenomas commonly have low-to-medium signal 
intensity on T1-weighted images and high signal intensity on T2-weighted images.  After 
gadolinium contrast administration, abnormal parathyroid glands show strong 
enhancement on T1-weighted images, comparable to conventional T2-weighted imaging.  
9.5 Parathyroid arteriography and venous sampling 
Parathyroid arteriography and parathyroid venous sampling are invasive tests burdened by 
a remarkable risk of embolic stroke and spinal cord injury, and therefore should be 
considered only when the findings of noninvasive imaging modalities are nondiagnostic.  
Parathyroid adenomas, like many endocrine tumors, tend to be hypervascular and have a 
characteristic appearance on angiograms. They appear as round or oval lesions with smooth 
margins and  dense  vascular blush. Localization of parathyroid adenoma may be visualized 
with use of digital subtraction angiography (DSA) and/or conventional arteriography. 
Thyrocervical trunks and common carotid arteries should be subject to selective 
arteriography in typical cases. Ectopic mediastinal or thymic glands may be better identified 
by examination of internal thoracic arteries. 
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Selective venous sampling with parathyroid hormone measurement may be performed to 
determine the general location of hypersecreting parathyroid tissue. Right and left thymic 
veins, inferior thyroid veins, and vertebral veins have been reported to be sampled in this 
regimen. A 2-fold gradient in PTH concentration in the sampled vein as referenced to that of 
the peripheral vein confirms the location of hyperactive parathyroid tissue. Similar 
technique may also be used intraoperatively to confirm curative resection of parathyroid 
adenoma. 
10. Preoperative anesthetic management 
Since renal function is likely to be impaired in hyperparathyroidism, prior to surgical 
treatment hypercalcemic patients require thorough rehydration. In some of these patients 
urinary catheterization and central venous pressure monitoring may be indicated. After 
rehydration, loop diuretics may be administered to decrease renal calcium reabsorption and 
promote urinary excretion, which in result will alleviate hypercalcaemia. Excessive diuresis 
may in turn lead to increased maintenance fluid requirements. Corticosteroids, 
bisphosphonates, calcium chelators such as trisodium edentate, calcitonin, or even dialysis 
are occasionally indicated in severe cases. Hypertension, if present, should be controlled 
with fast-acting antihypertensive medication. In patients with end-stage renal failure, 
perioperative invasive central venous pressure monitoring may be helpful for thorough 
monitoring of circulatory system. Occasionally, tumors of other organs may secrete PTH, for 
example, bronchial or tracheal carcinomas. This condition is called 
pseudohyperparathyroidism and should be brought to attention preoperatively to avoid 
intreaoperative ventilatory problems in theses rare cases when the lesion occludes bronchial 
or tracheal lumen. 
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